85 articles for Y Ma
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.
Tsinghua University
Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome.
National Institute of Biological Sciences
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.
Merck Research Laboratories
Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
Merck Research Laboratories
Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent ROR¿t inverse agonists.
Fudan University
Design, synthesis and docking study of novel tetracyclic oxindole derivatives asa-glucosidase inhibitors.
Key Laboratory of Industrial Fermentation Microbiology (Tianjin University of Science and Technology)
Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.
Merck Research Laboratories
Endomorphin analogues with mixedµ-opioid (MOP) receptor agonism/d-opioid (DOP) receptor antagonism and lackingß-arrestin2 recruitment activity.
Nanjing Medical University
Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Merck Research Laboratories
Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.
Glaxosmithkline
Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent ROR¿t inhibitors.
Glaxosmithkline
Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors.
Glaxosmithkline
Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors.
Nankai University
Deconstruction of thea4ß2 nicotinic acetylcholine receptor positive allosteric modulator desformylflustrabromine.
Virginia Commonwealth University
Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases.
Sichuan University
Synthesis and anticancer activities of ageladine A and structural analogs.
Beckman Research Institute At City of Hope
Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.
Schering-Plough Research Institute
Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876.
Virginia Commonwealth University School of Medicine
Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer.
Wenzhou Medical University
Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer.
Nankai University
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.
Texas A&M University
Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management.
Henan University
SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme.
Texas A&M University
Bipyridine Derivatives as NOP2/Sun RNA Methyltransferase 3 Inhibitors for the Treatment of Colorectal Cancer.
Zhejiang University
Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases.
Purdue University
Synthesis, anti-inflammatory activity, and conformational relationship studies of chromone derivatives incorporating amide groups.
Inner Mongolia Medical University
Discovery of unglycosylated indolocarbazoles as ROCK2 isoform-selective inhibitors for the treatment of breast cancer metastasis.
Zhejiang University
Covalent Peptide LSD1 Inhibitor Specifically Recognizes Cys360 in the Enzyme-Active Region.
Shenzhen University
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
Texas A&M University
Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis.
China Pharmaceutical University
Exploring gabosine and chlorogentisyl alcohol derivatives from a marine-derived fungus as EcGUS inhibitors with informatic assisted approaches.
Zhejiang University
PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism.
Nanjing University
Discovery of Pyxinol Amide Derivatives Bearing Amino Acid Residues as Nonsubstrate Allosteric Inhibitors of P-Glycoprotein-Mediated Multidrug Resistance.
Yantai University
Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates
Calithera Biosciences
Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis.
Shenzhen Salubris Pharmaceuticals Co.
Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia.
Shaanxi University of Science & Technology
Identification of 1,4-Benzodiazepine-2,5-dione Derivatives as Potential Protein Synthesis Inhibitors with Highly Potent Anticancer Activity.
Tsinghua University
Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents.
China Pharmaceutical University
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
Merck
Novel Hybrids of 3-Substituted Coumarin and Phenylsulfonylfuroxan as Potent Antitumor Agents with Collateral Sensitivity against MCF-7/ADR.
Fudan University
Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.
Shandong University
Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
China Pharmaceutical University
Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.
Merck
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
Texas A&M University
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
Texas A&M University
Potent Inhibition of HIF1α and p300 Interaction by a Constrained Peptide Derived from CITED2.
Peking University Shenzhen Graduate School
Optimization of bifunctional piperidinamide derivatives as σ
Huazhong University of Science and Technology
Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.
Shandong University
Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization.
The First Affiliated Hospital of Xi'An Jiaotong University
Identification of benzofused five-membered sultams, potent dual NOD1/NOD2 antagonists in vitro and in vivo.
Peking Union Medical College
Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
Shenyang Pharmaceutical University
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Beijing Normal University
Nonpeptidic quinazolinone derivatives as dual nucleotide-binding oligomerization domain-like receptor 1/2 antagonists for adjuvant cancer chemotherapy.
Peking Union Medical College
Discovery of an Inhibitor for the TREK-1 Channel Targeting an Intermediate Transition State of Channel Gating.
Shanghai Institute of Materia Medica
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
China Pharmaceutical University
Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue.
Peking Union Medical College
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
Xavier University of Louisiana
Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
National Institute of Biological Sciences (Nibs)
Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Nankai University
Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from
Fudan University
Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Aβ
Zhejiang Chinese Medical University
Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer's disease.
Zhejiang University
4-Iminooxazolidin-2-one as a Bioisostere of the Cyanohydrin Moiety: Inhibitors of Enterovirus 71 3C Protease.
Nankai University
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
University of California San Diego
Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer.
Nankai University
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
Celgene
Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.
Peking Union Medical College
Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors
Boehringer Ingelheim International
PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT
Korea Reserarch Institute of Chemical Technology
Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
Aurigene Discovery Technologies
Substituted pyrimidines for preventing or treating cancer and inflammatory diseases
Korea Research Institute of Chemical Technology
Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
Boehringer Ingelheim International